<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20150724023315N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-02-24</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>The effect of ozone on low back pain</public_title>
      <acronym></acronym>
      <scientific_title>Effectiveness of percutaneus epidural neuroplasty(RACZ procidures) with and without epidural OZONE injection in patients with chronic low back pain</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-02-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>38</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/68446</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization is done using the randomized permutation block with Excel software. The blocks are provided to the attending physician and when each patient enters, a block envelope is randomly selected and based on the sticker removed, the patient will be assigned to the relevant treatment group, Blinding description: In this study, those who register the results of the intervention and statistical analysis are not aware of what intervention was done for each patient and each group.</study_design>
      <phase>2-3</phase>
      <hc_freetext>chronic low back pain.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group(neuroplasty using the RACZ method plus ozone): The neuroplasty procedure of patients is performed in the operating room under aseptic conditions. The patient is placed in the prone position and standard monitoring (including blood pressure, ECG and pulse oximetry) and venous access are established and intravenous sedation with midazolam and fentanyl is prescribed. After the scraping, the doctor disinfects the area (waist, sacrum, and buttocks) with betadine, wearing a sterile gown, gloves, hat, and mask, and covers the patient's body with a sterile gown from the upper thoracic region to the knees. After the administration of prophylactic antibiotic (one gram of intravenous cefazolin), a 15G or 16G size epidural needle is inserted through the sacral hiatus under fluoroscopy guidance and 10 cc of contrast is injected to determine the location of the adhesion and defect. The RACZ catheter is inserted through the epidural needle and guided to the adhesion site or the area determined according to the patient's symptoms or MRI, and removal of the adhesion is done with mechanical maneuvers. In the next step, 1500 units of hyaluronidase dissolved in 10 cc of normal saline are injected, followed by 10 cc of 0.25% ropivacaine solution and 40 mg of methylprednisolone. in this group, 10 cc of ozone 25 micrograms per cc are injected. Finally, after 15 to 20 minutes, 5% hypertonic saline solution is injected in both groups for 15 minutes. At the end, the catheter is removed and the health of the catheter is checked. The patient is checked for sensory and motor deficits and is discharged home with education. Intervention 2: Control group(neuroplasty using the RACZ method): The neuroplasty procedure of patients is performed in the operating room under aseptic conditions. The patient is placed in the prone position and standard monitoring (including blood pressure, ECG and pulse oximetry) and venous access are established and intravenous sedation with midazolam and fentanyl is prescribed. After the scraping, the doctor disinfects the area (waist, sacrum, and buttocks) with betadine, wearing a sterile gown, gloves, hat, and mask, and covers the patient's body with a sterile gown from the upper thoracic region to the knees. After the administration of prophylactic antibiotic (one gram of intravenous cefazolin), a 15G or 16G size epidural needle is inserted through the sacral hiatus under fluoroscopy guidance and 10 cc of contrast is injected to determine the location of the adhesion and defect. The RACZ catheter is inserted through the epidural needle and guided to the adhesion site or the area determined according to the patient's symptoms or MRI, and removal of the adhesion is done with mechanical maneuvers. In the next step, 1500 units of hyaluronidase dissolved in 10 cc of normal saline are injected, followed by 10 cc of 0.25% ropivacaine solution and 40 mg of methylprednisolone.Finally, after 15 to 20 minutes, 5% hypertonic saline solution is injected in both groups for 15 minutes. At the end, the catheter is removed and the health of the catheter is checked. The patient is checked for sensory and motor deficits and is discharged home with education.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mahmoud Ganjifard</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 138, Nusrat St., Jamalzadeh St</address>
        <city>tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1419853851</zip>
        <telephone>+98 21 6119 2210</telephone>
        <email>fardganj@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mahmoud Ganjifard</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 138, Nusrat St., Jamalzadeh St</address>
        <city>tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1419853851</zip>
        <telephone>+98 21 6119 2210</telephone>
        <email>fardganj@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1- Radicular back pain for at least three months that has not responded to non-invasive treatments including medicine and physical therapy.
2- The pain score based on VNS (verbal numerical scale) should be more than 4</inclusion_criteria>
      <agemin>25 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with acute trauma and spinal fractures,
malignancies
rheumatic diseases
pregnancy
mental illnesses
peripheral neuropathies
hyperthyroidism
coagulopathy
chronic systemic infection
urinary and fecal incontinence
local infection of the sacrum area
patient dissatisfaction
favism</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>g55.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Nerve root and plexus compressions in intervertebral disc disorders</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group(neuroplasty using the RACZ method plus ozone): The neuroplasty procedure of patients is performed in the operating room under aseptic conditions. The patient is placed in the prone position and standard monitoring (including blood pressure, ECG and pulse oximetry) and venous access are established and intravenous sedation with midazolam and fentanyl is prescribed. After the scraping, the doctor disinfects the area (waist, sacrum, and buttocks) with betadine, wearing a sterile gown, gloves, hat, and mask, and covers the patient's body with a sterile gown from the upper thoracic region to the knees. After the administration of prophylactic antibiotic (one gram of intravenous cefazolin), a 15G or 16G size epidural needle is inserted through the sacral hiatus under fluoroscopy guidance and 10 cc of contrast is injected to determine the location of the adhesion and defect. The RACZ catheter is inserted through the epidural needle and guided to the adhesion site or the area determined according to the patient's symptoms or MRI, and removal of the adhesion is done with mechanical maneuvers. In the next step, 1500 units of hyaluronidase dissolved in 10 cc of normal saline are injected, followed by 10 cc of 0.25% ropivacaine solution and 40 mg of methylprednisolone. in this group, 10 cc of ozone 25 micrograms per cc are injected. Finally, after 15 to 20 minutes, 5% hypertonic saline solution is injected in both groups for 15 minutes. At the end, the catheter is removed and the health of the catheter is checked. The patient is checked for sensory and motor deficits and is discharged home with education.</i_keyword>
      <i_keyword>Control group(neuroplasty using the RACZ method): The neuroplasty procedure of patients is performed in the operating room under aseptic conditions. The patient is placed in the prone position and standard monitoring (including blood pressure, ECG and pulse oximetry) and venous access are established and intravenous sedation with midazolam and fentanyl is prescribed. After the scraping, the doctor disinfects the area (waist, sacrum, and buttocks) with betadine, wearing a sterile gown, gloves, hat, and mask, and covers the patient's body with a sterile gown from the upper thoracic region to the knees. After the administration of prophylactic antibiotic (one gram of intravenous cefazolin), a 15G or 16G size epidural needle is inserted through the sacral hiatus under fluoroscopy guidance and 10 cc of contrast is injected to determine the location of the adhesion and defect. The RACZ catheter is inserted through the epidural needle and guided to the adhesion site or the area determined according to the patient's symptoms or MRI, and removal of the adhesion is done with mechanical maneuvers. In the next step, 1500 units of hyaluronidase dissolved in 10 cc of normal saline are injected, followed by 10 cc of 0.25% ropivacaine solution and 40 mg of methylprednisolone.Finally, after 15 to 20 minutes, 5% hypertonic saline solution is injected in both groups for 15 minutes. At the end, the catheter is removed and the health of the catheter is checked. The patient is checked for sensory and motor deficits and is discharged home with education.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain intensity of patients based on verbal numeric scale (VNS). Timepoint: before the intervention, twenty-four hours, one month and three months after the intervention. Method of measurement: Pain intensity assessment questionnaire.</prim_outcome>
      <prim_outcome>The percentage of disability due to back pain based on the OSWESTRY disability index questionnaire. Timepoint: Before the intervention, one month and three months after the intervention. Method of measurement: OSWESTRY disability index questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-01-28</approval_date>
        <contact_name>Neuroscience Research Institute, Tehran University of Medical Sciences</contact_name>
        <contact_address>Keshavarz Boulevard tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
